| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GATA1 Transcription Factor | 18 | 2022 | 306 | 2.250 |
Why?
|
| Megakaryocytes | 12 | 2019 | 557 | 1.940 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 9 | 2023 | 355 | 1.450 |
Why?
|
| Erythroid Cells | 8 | 2019 | 237 | 1.430 |
Why?
|
| Erythropoiesis | 11 | 2019 | 692 | 1.070 |
Why?
|
| Transcription Factors | 29 | 2020 | 12159 | 1.050 |
Why?
|
| gamma-Globins | 3 | 2022 | 105 | 0.950 |
Why?
|
| DNA-Binding Proteins | 25 | 2020 | 9613 | 0.860 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2022 | 119 | 0.800 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 49 | 0.800 |
Why?
|
| Hematopoiesis | 9 | 2021 | 2060 | 0.790 |
Why?
|
| Hemangioblasts | 1 | 2021 | 29 | 0.770 |
Why?
|
| Anemia, Hemolytic | 1 | 2022 | 164 | 0.750 |
Why?
|
| Cell Differentiation | 13 | 2021 | 11657 | 0.750 |
Why?
|
| Core Binding Factor alpha Subunits | 1 | 2020 | 25 | 0.700 |
Why?
|
| Leukemia, Myeloid | 1 | 2022 | 694 | 0.640 |
Why?
|
| Hemolysis | 1 | 2021 | 417 | 0.630 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2021 | 3408 | 0.610 |
Why?
|
| Fanconi Anemia | 1 | 2020 | 327 | 0.570 |
Why?
|
| Erythroid Precursor Cells | 3 | 2011 | 211 | 0.560 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2021 | 328 | 0.560 |
Why?
|
| Gardening | 4 | 2018 | 18 | 0.540 |
Why?
|
| Promoter Regions, Genetic | 5 | 2017 | 5795 | 0.510 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2021 | 587 | 0.500 |
Why?
|
| Neurofibromatosis 1 | 5 | 2020 | 561 | 0.500 |
Why?
|
| src-Family Kinases | 3 | 2015 | 539 | 0.490 |
Why?
|
| Sentinel Lymph Node Biopsy | 11 | 2006 | 734 | 0.480 |
Why?
|
| Nuclear Proteins | 16 | 2012 | 5795 | 0.470 |
Why?
|
| Clostridium Infections | 1 | 2021 | 563 | 0.450 |
Why?
|
| Down Syndrome | 1 | 2022 | 916 | 0.440 |
Why?
|
| Palladium | 5 | 2006 | 67 | 0.440 |
Why?
|
| Embryonic Stem Cells | 6 | 2010 | 1244 | 0.430 |
Why?
|
| Dynamin III | 1 | 2012 | 5 | 0.430 |
Why?
|
| Zinc Fingers | 6 | 2016 | 577 | 0.420 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2012 | 42 | 0.400 |
Why?
|
| Brachytherapy | 8 | 2006 | 1221 | 0.390 |
Why?
|
| DNA Damage | 3 | 2020 | 2469 | 0.380 |
Why?
|
| Cell Lineage | 5 | 2012 | 2573 | 0.380 |
Why?
|
| Repressor Proteins | 5 | 2012 | 2979 | 0.380 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 2429 | 0.370 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 224 | 0.370 |
Why?
|
| GATA2 Transcription Factor | 4 | 2023 | 158 | 0.370 |
Why?
|
| Radioisotopes | 5 | 2006 | 509 | 0.360 |
Why?
|
| Carrier Proteins | 13 | 2015 | 4926 | 0.360 |
Why?
|
| Globins | 1 | 2011 | 405 | 0.350 |
Why?
|
| Erythrocytes | 6 | 2020 | 2412 | 0.350 |
Why?
|
| Thrombopoiesis | 1 | 2012 | 160 | 0.340 |
Why?
|
| Chromatin | 3 | 2012 | 2980 | 0.340 |
Why?
|
| Cell Line | 13 | 2021 | 15564 | 0.330 |
Why?
|
| Blood Platelet Disorders | 2 | 2021 | 60 | 0.330 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 10 | 2005 | 195 | 0.330 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2009 | 104 | 0.310 |
Why?
|
| Zebrafish Proteins | 4 | 2011 | 1018 | 0.310 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1751 | 0.300 |
Why?
|
| Gene Expression Regulation, Developmental | 6 | 2019 | 3610 | 0.290 |
Why?
|
| Sepsis | 1 | 2021 | 2604 | 0.280 |
Why?
|
| Protein Binding | 10 | 2019 | 9326 | 0.270 |
Why?
|
| Breast Neoplasms | 26 | 2018 | 21162 | 0.270 |
Why?
|
| Oligosaccharides | 4 | 1992 | 406 | 0.270 |
Why?
|
| Neoplasm Proteins | 5 | 2012 | 3600 | 0.260 |
Why?
|
| Cathepsin D | 4 | 1992 | 59 | 0.260 |
Why?
|
| Angioplasty, Balloon | 2 | 2000 | 592 | 0.250 |
Why?
|
| Humans | 195 | 2023 | 766812 | 0.250 |
Why?
|
| Mice | 38 | 2021 | 81898 | 0.240 |
Why?
|
| Zebrafish | 8 | 2020 | 3035 | 0.240 |
Why?
|
| Genomics | 2 | 2021 | 5922 | 0.240 |
Why?
|
| Animals | 52 | 2021 | 168939 | 0.240 |
Why?
|
| Biotinylation | 3 | 2009 | 184 | 0.240 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 3 | 1992 | 35 | 0.240 |
Why?
|
| Blood Platelets | 3 | 2019 | 2465 | 0.240 |
Why?
|
| Prostatic Hyperplasia | 4 | 2012 | 514 | 0.230 |
Why?
|
| Administrative Personnel | 1 | 2005 | 185 | 0.230 |
Why?
|
| Neurofibroma, Plexiform | 2 | 2014 | 66 | 0.220 |
Why?
|
| Heme | 2 | 2017 | 316 | 0.220 |
Why?
|
| Phosphotransferases | 3 | 1992 | 302 | 0.220 |
Why?
|
| Vegetables | 3 | 2018 | 1199 | 0.210 |
Why?
|
| beta-Globins | 2 | 2022 | 111 | 0.210 |
Why?
|
| Lymph Node Excision | 7 | 2006 | 1267 | 0.210 |
Why?
|
| Myocardial Ischemia | 3 | 1998 | 2131 | 0.210 |
Why?
|
| Neoplasm Staging | 33 | 2015 | 11218 | 0.200 |
Why?
|
| Lung Neoplasms | 18 | 2010 | 13489 | 0.200 |
Why?
|
| Genome | 2 | 2011 | 1753 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2014 | 11876 | 0.200 |
Why?
|
| Survival Analysis | 23 | 2013 | 10101 | 0.200 |
Why?
|
| Spinal Cord Ischemia | 1 | 2003 | 94 | 0.200 |
Why?
|
| Gene Expression Regulation | 10 | 2020 | 11924 | 0.190 |
Why?
|
| Genome, Human | 2 | 2012 | 4443 | 0.190 |
Why?
|
| Mutation | 15 | 2022 | 30214 | 0.190 |
Why?
|
| Clostridium perfringens | 1 | 2021 | 29 | 0.190 |
Why?
|
| Adenocarcinoma | 9 | 2005 | 6359 | 0.190 |
Why?
|
| Mast Cells | 2 | 2008 | 1405 | 0.180 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 502 | 0.180 |
Why?
|
| Gene Expression Profiling | 9 | 2012 | 9528 | 0.180 |
Why?
|
| Trisomy | 1 | 2022 | 260 | 0.180 |
Why?
|
| Transcription, Genetic | 10 | 2020 | 7612 | 0.180 |
Why?
|
| Research Personnel | 1 | 2005 | 589 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 3633 | 0.180 |
Why?
|
| Polyethylene Terephthalates | 1 | 2000 | 112 | 0.180 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 1998 | 1457 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2006 | 2801 | 0.180 |
Why?
|
| Alloys | 1 | 2000 | 110 | 0.180 |
Why?
|
| Electrocardiography | 3 | 1998 | 6408 | 0.170 |
Why?
|
| Lovastatin | 2 | 2019 | 114 | 0.170 |
Why?
|
| Male | 100 | 2022 | 364154 | 0.170 |
Why?
|
| Prostatic Neoplasms | 11 | 2006 | 11094 | 0.170 |
Why?
|
| Middle Aged | 90 | 2021 | 223267 | 0.170 |
Why?
|
| Sirolimus | 3 | 2020 | 1540 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2010 | 8623 | 0.170 |
Why?
|
| Ultraviolet Rays | 2 | 2015 | 1100 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 1131 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2008 | 5389 | 0.170 |
Why?
|
| Hypothyroidism | 2 | 2004 | 665 | 0.160 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2020 | 187 | 0.160 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 1886 | 0.160 |
Why?
|
| Lymphatic Metastasis | 12 | 2006 | 2901 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 8045 | 0.160 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2019 | 19 | 0.160 |
Why?
|
| Leukemia | 2 | 2023 | 1521 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 6 | 2014 | 2902 | 0.160 |
Why?
|
| Neuroblastoma | 10 | 1997 | 1266 | 0.160 |
Why?
|
| Lysosomes | 3 | 1992 | 937 | 0.160 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2000 | 314 | 0.150 |
Why?
|
| Plant Extracts | 2 | 2012 | 496 | 0.150 |
Why?
|
| Laryngectomy | 1 | 2000 | 245 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 4652 | 0.150 |
Why?
|
| Molecular Sequence Data | 12 | 2011 | 17609 | 0.150 |
Why?
|
| Aged | 76 | 2021 | 171344 | 0.150 |
Why?
|
| Endonucleases | 4 | 2010 | 371 | 0.150 |
Why?
|
| Female | 115 | 2021 | 396532 | 0.150 |
Why?
|
| Phosphorylation | 10 | 2015 | 8310 | 0.150 |
Why?
|
| Androgen Antagonists | 4 | 2012 | 1411 | 0.150 |
Why?
|
| Ploidies | 4 | 2008 | 287 | 0.150 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 209 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 2060 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1561 | 0.150 |
Why?
|
| Aged, 80 and over | 43 | 2018 | 59548 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 8 | 2014 | 1097 | 0.140 |
Why?
|
| Heterozygote | 2 | 2022 | 2795 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2021 | 3093 | 0.140 |
Why?
|
| Renal Agents | 1 | 1997 | 30 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2015 | 4523 | 0.140 |
Why?
|
| Exercise | 4 | 2018 | 5945 | 0.140 |
Why?
|
| Signal Transduction | 9 | 2017 | 23618 | 0.140 |
Why?
|
| Enuresis | 1 | 1997 | 45 | 0.140 |
Why?
|
| Chromatography, Affinity | 4 | 2012 | 524 | 0.140 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2017 | 57 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2005 | 710 | 0.140 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 1997 | 87 | 0.140 |
Why?
|
| Adult | 81 | 2021 | 223305 | 0.140 |
Why?
|
| Laryngeal Neoplasms | 1 | 2000 | 514 | 0.140 |
Why?
|
| Cytokines | 1 | 2012 | 7438 | 0.130 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 13644 | 0.130 |
Why?
|
| Mice, Knockout | 8 | 2019 | 14473 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 1392 | 0.130 |
Why?
|
| Angioplasty | 1 | 1999 | 355 | 0.130 |
Why?
|
| Employment | 1 | 2002 | 1110 | 0.130 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 1110 | 0.130 |
Why?
|
| Carcinoma, Lobular | 6 | 2014 | 480 | 0.130 |
Why?
|
| Neoplasms | 13 | 2021 | 22350 | 0.130 |
Why?
|
| Enzyme Precursors | 2 | 1992 | 166 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 3610 | 0.130 |
Why?
|
| Cyclins | 3 | 2003 | 605 | 0.130 |
Why?
|
| Infant, Newborn | 9 | 2022 | 26387 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 6 | 2012 | 2463 | 0.130 |
Why?
|
| Mannose | 2 | 1992 | 121 | 0.120 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 17089 | 0.120 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1999 | 538 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 5 | 2006 | 872 | 0.120 |
Why?
|
| Protein Interaction Mapping | 2 | 2009 | 621 | 0.120 |
Why?
|
| Urine | 1 | 1997 | 363 | 0.120 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2015 | 83 | 0.120 |
Why?
|
| Binding Sites | 7 | 2011 | 6013 | 0.120 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2016 | 279 | 0.120 |
Why?
|
| Survival Rate | 23 | 2014 | 12826 | 0.120 |
Why?
|
| Leg | 2 | 1999 | 1087 | 0.120 |
Why?
|
| Florida | 9 | 2016 | 417 | 0.120 |
Why?
|
| Trans-Activators | 5 | 2005 | 2856 | 0.120 |
Why?
|
| Prognosis | 37 | 2014 | 29959 | 0.110 |
Why?
|
| Phenotype | 4 | 2022 | 16722 | 0.110 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2016 | 184 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 16044 | 0.110 |
Why?
|
| Ergometry | 1 | 1993 | 17 | 0.110 |
Why?
|
| Sunbathing | 1 | 2014 | 66 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 1657 | 0.110 |
Why?
|
| Predictive Value of Tests | 18 | 2015 | 15425 | 0.110 |
Why?
|
| Erythropoietin | 2 | 2017 | 718 | 0.110 |
Why?
|
| Thallium Radioisotopes | 3 | 1998 | 138 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2001 | 934 | 0.110 |
Why?
|
| Cancer Vaccines | 3 | 2008 | 1042 | 0.110 |
Why?
|
| Granulocytes | 1 | 2015 | 551 | 0.110 |
Why?
|
| Income | 1 | 2002 | 1876 | 0.110 |
Why?
|
| Leucine | 1 | 2015 | 547 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2001 | 1806 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 2902 | 0.110 |
Why?
|
| Cosmetics | 1 | 2014 | 104 | 0.110 |
Why?
|
| Radiometry | 2 | 2011 | 814 | 0.110 |
Why?
|
| Glioblastoma | 3 | 2014 | 3458 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 1172 | 0.110 |
Why?
|
| Histone Deacetylases | 2 | 2015 | 712 | 0.110 |
Why?
|
| Verapamil | 1 | 1993 | 242 | 0.110 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 170 | 0.110 |
Why?
|
| Genes, BRCA2 | 2 | 2007 | 591 | 0.110 |
Why?
|
| Aging | 4 | 2001 | 8728 | 0.100 |
Why?
|
| Melanoma | 7 | 2015 | 5702 | 0.100 |
Why?
|
| Postpartum Hemorrhage | 1 | 2016 | 275 | 0.100 |
Why?
|
| Streptavidin | 2 | 2009 | 81 | 0.100 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 193 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 857 | 0.100 |
Why?
|
| Electron Transport Complex IV | 1 | 2013 | 188 | 0.100 |
Why?
|
| Stillbirth | 1 | 2016 | 381 | 0.100 |
Why?
|
| Mice, Transgenic | 8 | 2012 | 9546 | 0.100 |
Why?
|
| Asparagine | 1 | 1992 | 120 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2004 | 2085 | 0.100 |
Why?
|
| DNA | 5 | 2015 | 7210 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2002 | 1949 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 10 | 2015 | 22351 | 0.100 |
Why?
|
| Glioma | 2 | 2020 | 3498 | 0.100 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2010 | 121 | 0.100 |
Why?
|
| K562 Cells | 2 | 2011 | 644 | 0.100 |
Why?
|
| Live Birth | 1 | 2016 | 516 | 0.100 |
Why?
|
| Child, Preschool | 19 | 2022 | 42577 | 0.100 |
Why?
|
| Fruit | 1 | 2018 | 1166 | 0.100 |
Why?
|
| Disease-Free Survival | 10 | 2014 | 6853 | 0.100 |
Why?
|
| Tritium | 1 | 1992 | 707 | 0.100 |
Why?
|
| Prostatectomy | 3 | 2005 | 1785 | 0.100 |
Why?
|
| Chemokines | 1 | 2016 | 963 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2014 | 1163 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2007 | 376 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2001 | 3642 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2005 | 476 | 0.100 |
Why?
|
| Hemoglobins | 2 | 2015 | 1531 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2012 | 93 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 3759 | 0.100 |
Why?
|
| Sialoglycoproteins | 2 | 2003 | 316 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2016 | 245 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1925 | 0.100 |
Why?
|
| Ribosomes | 1 | 2015 | 496 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2009 | 792 | 0.090 |
Why?
|
| Home Care Services | 1 | 2018 | 659 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1604 | 0.090 |
Why?
|
| Magnetic Field Therapy | 1 | 2011 | 27 | 0.090 |
Why?
|
| Mastectomy | 3 | 2014 | 1861 | 0.090 |
Why?
|
| Cytoskeleton | 1 | 2016 | 1179 | 0.090 |
Why?
|
| Urination | 1 | 2012 | 204 | 0.090 |
Why?
|
| Base Sequence | 8 | 2013 | 12415 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2007 | 542 | 0.090 |
Why?
|
| Glycoproteins | 2 | 2004 | 2201 | 0.090 |
Why?
|
| Infant | 18 | 2022 | 36459 | 0.090 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 703 | 0.090 |
Why?
|
| Isotope Labeling | 1 | 1992 | 390 | 0.090 |
Why?
|
| Phosphoproteins | 2 | 2015 | 2448 | 0.090 |
Why?
|
| T-Lymphocytes | 5 | 2016 | 10263 | 0.090 |
Why?
|
| Combined Modality Therapy | 13 | 2014 | 8540 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 3 | 2005 | 2930 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 932 | 0.090 |
Why?
|
| Smoking | 2 | 2004 | 9077 | 0.090 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2011 | 88 | 0.090 |
Why?
|
| Etoposide | 3 | 2010 | 638 | 0.090 |
Why?
|
| Retrospective Studies | 34 | 2016 | 81657 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 1997 | 1155 | 0.090 |
Why?
|
| Brain Neoplasms | 5 | 2014 | 9101 | 0.090 |
Why?
|
| Models, Biological | 4 | 2011 | 9464 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2012 | 297 | 0.090 |
Why?
|
| Urination Disorders | 1 | 2011 | 236 | 0.090 |
Why?
|
| Community Health Centers | 2 | 2004 | 469 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 2 | 2006 | 534 | 0.090 |
Why?
|
| Interleukin-2 | 3 | 2008 | 1895 | 0.090 |
Why?
|
| Deoxycytidine | 4 | 2010 | 886 | 0.090 |
Why?
|
| Research Design | 4 | 2016 | 6206 | 0.090 |
Why?
|
| Liver Neoplasms | 5 | 2011 | 4356 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2005 | 3459 | 0.080 |
Why?
|
| Cells, Cultured | 5 | 2015 | 18986 | 0.080 |
Why?
|
| Wound Healing | 1 | 2000 | 2800 | 0.080 |
Why?
|
| Embryo, Nonmammalian | 2 | 2015 | 910 | 0.080 |
Why?
|
| Sensitivity and Specificity | 12 | 2015 | 14653 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2002 | 2703 | 0.080 |
Why?
|
| Sequence Deletion | 3 | 2002 | 1494 | 0.080 |
Why?
|
| Adolescent | 31 | 2021 | 88902 | 0.080 |
Why?
|
| Skin Neoplasms | 5 | 2015 | 5860 | 0.080 |
Why?
|
| Flutamide | 2 | 2000 | 95 | 0.080 |
Why?
|
| Amino Acid Sequence | 7 | 2008 | 13411 | 0.080 |
Why?
|
| Child | 28 | 2021 | 80670 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2011 | 4892 | 0.080 |
Why?
|
| Hodgkin Disease | 5 | 1997 | 1384 | 0.080 |
Why?
|
| Stents | 1 | 2000 | 3193 | 0.080 |
Why?
|
| Valproic Acid | 1 | 2011 | 444 | 0.080 |
Why?
|
| Biotin | 1 | 2009 | 255 | 0.080 |
Why?
|
| Germ Cells | 2 | 2023 | 644 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2012 | 10745 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2008 | 4050 | 0.080 |
Why?
|
| Disease Progression | 8 | 2019 | 13642 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2011 | 751 | 0.080 |
Why?
|
| Immunohistochemistry | 11 | 2013 | 11062 | 0.080 |
Why?
|
| Methods | 1 | 2008 | 1065 | 0.080 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 743 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 419 | 0.080 |
Why?
|
| Single Person | 1 | 1988 | 31 | 0.080 |
Why?
|
| Radionuclide Imaging | 5 | 2002 | 1986 | 0.070 |
Why?
|
| Hepatic Artery | 2 | 2006 | 233 | 0.070 |
Why?
|
| Carbohydrate Sequence | 3 | 1992 | 411 | 0.070 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 714 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2009 | 826 | 0.070 |
Why?
|
| Gamma Rays | 2 | 2007 | 324 | 0.070 |
Why?
|
| Yolk Sac | 1 | 2008 | 79 | 0.070 |
Why?
|
| Animals, Genetically Modified | 2 | 2015 | 1562 | 0.070 |
Why?
|
| Executive Function | 1 | 2016 | 1396 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2014 | 36570 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2010 | 1998 | 0.070 |
Why?
|
| Follow-Up Studies | 11 | 2014 | 39312 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2003 | 2694 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 9244 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2010 | 617 | 0.070 |
Why?
|
| Leuprolide | 2 | 2000 | 310 | 0.070 |
Why?
|
| Diet | 2 | 2018 | 8088 | 0.070 |
Why?
|
| Vinblastine | 3 | 2005 | 482 | 0.070 |
Why?
|
| Biopsy | 7 | 2015 | 6779 | 0.070 |
Why?
|
| Treatment Outcome | 23 | 2014 | 65286 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2012 | 1646 | 0.070 |
Why?
|
| Mice, Mutant Strains | 2 | 2008 | 1751 | 0.070 |
Why?
|
| Uncertainty | 2 | 2003 | 765 | 0.070 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2012 | 724 | 0.070 |
Why?
|
| Paget's Disease, Mammary | 1 | 2006 | 18 | 0.070 |
Why?
|
| Probability | 6 | 2005 | 2476 | 0.070 |
Why?
|
| Camptothecin | 2 | 2010 | 599 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2015 | 4570 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 1729 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 20146 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2012 | 961 | 0.070 |
Why?
|
| Adenoma | 3 | 2004 | 2155 | 0.070 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 200 | 0.070 |
Why?
|
| Genes, myc | 4 | 1997 | 391 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 9 | 2008 | 6105 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 304 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2009 | 657 | 0.060 |
Why?
|
| Abdominal Cavity | 1 | 2006 | 34 | 0.060 |
Why?
|
| Prospective Studies | 22 | 2015 | 54872 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 646 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 1995 | 3446 | 0.060 |
Why?
|
| Fetal Hemoglobin | 1 | 2008 | 346 | 0.060 |
Why?
|
| Genotype | 2 | 2019 | 13036 | 0.060 |
Why?
|
| Colonic Neoplasms | 3 | 2003 | 2535 | 0.060 |
Why?
|
| Logistic Models | 7 | 2005 | 13276 | 0.060 |
Why?
|
| Exercise Test | 3 | 1998 | 2188 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 899 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2006 | 892 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 1206 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2018 | 5306 | 0.060 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2006 | 158 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4277 | 0.060 |
Why?
|
| Genes, BRCA1 | 2 | 2007 | 753 | 0.060 |
Why?
|
| Serine | 1 | 2009 | 828 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 5753 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 6 | 2013 | 6066 | 0.060 |
Why?
|
| Keratins | 3 | 2002 | 499 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 1029 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 996 | 0.060 |
Why?
|
| Quality of Life | 8 | 2018 | 13476 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2721 | 0.060 |
Why?
|
| Pilot Projects | 7 | 2018 | 8728 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2006 | 528 | 0.060 |
Why?
|
| Apoptosis | 8 | 2007 | 9514 | 0.060 |
Why?
|
| Iodine Radioisotopes | 3 | 2006 | 1030 | 0.060 |
Why?
|
| Family | 1 | 1995 | 3209 | 0.060 |
Why?
|
| Mitochondrial Membranes | 2 | 2017 | 185 | 0.060 |
Why?
|
| Health Behavior | 3 | 2018 | 2649 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 2007 | 4903 | 0.060 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2006 | 249 | 0.060 |
Why?
|
| Gene Expression | 5 | 2015 | 7585 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2009 | 722 | 0.060 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2004 | 29 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 225 | 0.060 |
Why?
|
| Ganglioneuroma | 3 | 1993 | 53 | 0.060 |
Why?
|
| Colorectal Neoplasms | 4 | 2006 | 6965 | 0.060 |
Why?
|
| Somatostatin | 1 | 2006 | 459 | 0.050 |
Why?
|
| Forms and Records Control | 1 | 2004 | 158 | 0.050 |
Why?
|
| Premature Birth | 1 | 2016 | 1830 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2014 | 9407 | 0.050 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.050 |
Why?
|
| Premenopause | 2 | 2005 | 1039 | 0.050 |
Why?
|
| Surgicenters | 1 | 2003 | 37 | 0.050 |
Why?
|
| Carcinoma in Situ | 2 | 2007 | 784 | 0.050 |
Why?
|
| Acute-Phase Reaction | 1 | 2003 | 91 | 0.050 |
Why?
|
| Isoflavones | 1 | 2004 | 139 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2003 | 60 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2008 | 2413 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2009 | 1505 | 0.050 |
Why?
|
| Tretinoin | 1 | 2006 | 524 | 0.050 |
Why?
|
| Axilla | 5 | 2006 | 622 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2003 | 113 | 0.050 |
Why?
|
| Precancerous Conditions | 2 | 2007 | 980 | 0.050 |
Why?
|
| Ki-67 Antigen | 4 | 2007 | 630 | 0.050 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2003 | 112 | 0.050 |
Why?
|
| Tryptophan Oxygenase | 1 | 2002 | 19 | 0.050 |
Why?
|
| Age Distribution | 2 | 2005 | 2869 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2006 | 287 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 415 | 0.050 |
Why?
|
| Paraplegia | 1 | 2003 | 161 | 0.050 |
Why?
|
| Carbohydrate Conformation | 2 | 1992 | 206 | 0.050 |
Why?
|
| Triterpenes | 1 | 2003 | 78 | 0.050 |
Why?
|
| Serenoa | 2 | 2012 | 11 | 0.050 |
Why?
|
| Lymph Nodes | 4 | 2002 | 3468 | 0.050 |
Why?
|
| Carboplatin | 4 | 2010 | 790 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2012 | 1900 | 0.050 |
Why?
|
| Mouth Mucosa | 2 | 2011 | 434 | 0.050 |
Why?
|
| Survivors | 1 | 2013 | 2379 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2011 | 2329 | 0.050 |
Why?
|
| Plasmids | 3 | 2009 | 2268 | 0.050 |
Why?
|
| Sphingosine | 1 | 2004 | 306 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 160 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2001 | 30 | 0.050 |
Why?
|
| Doxorubicin | 8 | 2006 | 2229 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2004 | 293 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2006 | 2596 | 0.050 |
Why?
|
| Genistein | 1 | 2002 | 87 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2004 | 15831 | 0.050 |
Why?
|
| Personality | 1 | 2005 | 560 | 0.050 |
Why?
|
| Medical Records | 2 | 2004 | 1408 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2004 | 336 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 1752 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 4056 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2005 | 10384 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2005 | 1989 | 0.050 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 3485 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2005 | 2603 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2005 | 548 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2007 | 2841 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2011 | 2631 | 0.050 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 3 | 2006 | 31 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 505 | 0.050 |
Why?
|
| Risk Factors | 13 | 2006 | 74889 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2016 | 3850 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 996 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2019 | 12430 | 0.050 |
Why?
|
| Receptors, Estrogen | 4 | 2013 | 2252 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2005 | 706 | 0.050 |
Why?
|
| Amphotericin B | 2 | 2002 | 140 | 0.050 |
Why?
|
| Anemia | 2 | 2014 | 1514 | 0.050 |
Why?
|
| Cloning, Molecular | 4 | 1999 | 4168 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2010 | 12536 | 0.050 |
Why?
|
| Estrone | 1 | 2002 | 234 | 0.050 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2002 | 175 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 1998 | 2916 | 0.050 |
Why?
|
| Mitochondria | 1 | 2014 | 3678 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2021 | 159 | 0.050 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 3440 | 0.040 |
Why?
|
| Response Elements | 1 | 2002 | 308 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2000 | 1536 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 3723 | 0.040 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2000 | 69 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 279 | 0.040 |
Why?
|
| Smad1 Protein | 1 | 2020 | 81 | 0.040 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2000 | 55 | 0.040 |
Why?
|
| Quinazolines | 2 | 2005 | 1367 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 697 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2023 | 385 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 1073 | 0.040 |
Why?
|
| Mass Screening | 4 | 2004 | 5454 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2005 | 2274 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2004 | 5536 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2014 | 3576 | 0.040 |
Why?
|
| Tryptophan | 1 | 2002 | 484 | 0.040 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2004 | 323 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2005 | 12064 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2001 | 6329 | 0.040 |
Why?
|
| Quinolones | 1 | 2004 | 389 | 0.040 |
Why?
|
| Mitotic Index | 2 | 2000 | 160 | 0.040 |
Why?
|
| Aneurysm | 1 | 2003 | 343 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2002 | 251 | 0.040 |
Why?
|
| Family Relations | 1 | 2002 | 318 | 0.040 |
Why?
|
| Liver | 3 | 2014 | 7571 | 0.040 |
Why?
|
| Research Support as Topic | 2 | 2003 | 697 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 3186 | 0.040 |
Why?
|
| Cell Division | 6 | 2003 | 4473 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 2015 | 458 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2020 | 1366 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2019 | 1716 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2000 | 122 | 0.040 |
Why?
|
| Retroviridae | 1 | 2002 | 846 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2004 | 3230 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2004 | 490 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2009 | 3446 | 0.040 |
Why?
|
| Image Cytometry | 1 | 1999 | 51 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 784 | 0.040 |
Why?
|
| Multiple Myeloma | 3 | 2004 | 5193 | 0.040 |
Why?
|
| Oocytes | 3 | 1992 | 1168 | 0.040 |
Why?
|
| Phylogeny | 2 | 2004 | 2840 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 659 | 0.040 |
Why?
|
| Candidiasis | 1 | 2002 | 372 | 0.040 |
Why?
|
| Emotions | 2 | 2014 | 2758 | 0.040 |
Why?
|
| Aortography | 1 | 2000 | 423 | 0.040 |
Why?
|
| Algorithms | 7 | 2011 | 14073 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2003 | 452 | 0.040 |
Why?
|
| Endometrial Hyperplasia | 1 | 1999 | 102 | 0.040 |
Why?
|
| Radiation Oncology | 1 | 2005 | 572 | 0.040 |
Why?
|
| Life Tables | 1 | 1999 | 367 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4780 | 0.040 |
Why?
|
| Xenopus laevis | 2 | 1992 | 966 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 4282 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 539 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2010 | 108 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 498 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2006 | 638 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1057 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2005 | 3552 | 0.040 |
Why?
|
| Estradiol | 2 | 2004 | 1947 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2004 | 1469 | 0.040 |
Why?
|
| Mastectomy, Segmental | 2 | 2001 | 974 | 0.040 |
Why?
|
| Social Desirability | 1 | 2018 | 45 | 0.040 |
Why?
|
| Body Composition | 2 | 2005 | 2441 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1999 | 198 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2007 | 2875 | 0.040 |
Why?
|
| Genes, ras | 1 | 2000 | 656 | 0.040 |
Why?
|
| Age Factors | 9 | 2005 | 18397 | 0.040 |
Why?
|
| Alabama | 1 | 2018 | 111 | 0.040 |
Why?
|
| Restriction Mapping | 3 | 1992 | 848 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2000 | 627 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 1988 | 2193 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 5690 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 314 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2010 | 1497 | 0.040 |
Why?
|
| Pedigree | 2 | 2021 | 4539 | 0.040 |
Why?
|
| Random Allocation | 2 | 2003 | 2394 | 0.040 |
Why?
|
| Ifosfamide | 2 | 1995 | 233 | 0.040 |
Why?
|
| Computational Biology | 1 | 2009 | 3564 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 1228 | 0.040 |
Why?
|
| Islets of Langerhans | 2 | 1995 | 1350 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2010 | 5330 | 0.040 |
Why?
|
| Young Adult | 8 | 2019 | 59939 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 1159 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 1998 | 299 | 0.040 |
Why?
|
| Eosinophils | 1 | 2002 | 952 | 0.040 |
Why?
|
| Rabbits | 1 | 2003 | 4752 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 1997 | 115 | 0.030 |
Why?
|
| Vincristine | 5 | 2000 | 1040 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2001 | 1075 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 1374 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 11514 | 0.030 |
Why?
|
| False Negative Reactions | 3 | 2002 | 570 | 0.030 |
Why?
|
| Perinatology | 1 | 2016 | 64 | 0.030 |
Why?
|
| Time Factors | 5 | 2011 | 40149 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2016 | 3587 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2005 | 2921 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1997 | 594 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 1403 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1992 | 292 | 0.030 |
Why?
|
| Observer Variation | 2 | 2000 | 2614 | 0.030 |
Why?
|
| Siblings | 1 | 2020 | 828 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1997 | 655 | 0.030 |
Why?
|
| Dogs | 1 | 2000 | 3834 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2003 | 2669 | 0.030 |
Why?
|
| Sarcoma | 2 | 1998 | 1802 | 0.030 |
Why?
|
| Health Surveys | 1 | 2005 | 4055 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1999 | 915 | 0.030 |
Why?
|
| Amino Acid Transport Systems, Basic | 1 | 2015 | 35 | 0.030 |
Why?
|
| Insulin Antibodies | 1 | 1995 | 28 | 0.030 |
Why?
|
| Receptor, erbB-2 | 3 | 2013 | 2598 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2013 | 6214 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 372 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2003 | 1811 | 0.030 |
Why?
|
| Proteomics | 1 | 2009 | 3915 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1997 | 242 | 0.030 |
Why?
|
| Treatment Failure | 2 | 1999 | 2659 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3073 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1997 | 482 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2016 | 740 | 0.030 |
Why?
|
| DNA Primers | 2 | 2013 | 2826 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 482 | 0.030 |
Why?
|
| Protein Conformation | 2 | 1992 | 3948 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2011 | 877 | 0.030 |
Why?
|
| Placebos | 3 | 2004 | 1659 | 0.030 |
Why?
|
| Fluorouracil | 3 | 2010 | 1652 | 0.030 |
Why?
|
| Weight Gain | 3 | 2004 | 2356 | 0.030 |
Why?
|
| Urinalysis | 1 | 1997 | 369 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 2016 | 285 | 0.030 |
Why?
|
| Transfection | 4 | 2008 | 5755 | 0.030 |
Why?
|
| Veins | 1 | 1999 | 769 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 2003 | 1622 | 0.030 |
Why?
|
| Glycopeptides | 2 | 1992 | 225 | 0.030 |
Why?
|
| Gene Amplification | 3 | 1997 | 1088 | 0.030 |
Why?
|
| Spleen | 1 | 2020 | 2295 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 2014 | 167 | 0.030 |
Why?
|
| Fetal Death | 1 | 2016 | 434 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2018 | 934 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 757 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 4787 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 578 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 2426 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 1276 | 0.030 |
Why?
|
| Xenopus | 2 | 1992 | 710 | 0.030 |
Why?
|
| Sex Factors | 3 | 2004 | 10619 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 337 | 0.030 |
Why?
|
| RNA Interference | 2 | 2015 | 2829 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2006 | 1405 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2006 | 896 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2325 | 0.030 |
Why?
|
| Hypertension | 1 | 1993 | 8616 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 2952 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 1993 | 149 | 0.030 |
Why?
|
| Perfusion | 1 | 1998 | 1409 | 0.030 |
Why?
|
| Pepsinogens | 1 | 1992 | 7 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 3796 | 0.030 |
Why?
|
| Occult Blood | 2 | 2004 | 199 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2001 | 2606 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 18076 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2010 | 406 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 1639 | 0.030 |
Why?
|
| General Surgery | 2 | 2001 | 1720 | 0.030 |
Why?
|
| Extremities | 1 | 1998 | 869 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2015 | 369 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2002 | 1209 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1997 | 967 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 1788 | 0.030 |
Why?
|
| Cohort Studies | 6 | 2019 | 41706 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2000 | 957 | 0.030 |
Why?
|
| Glycoside Hydrolases | 1 | 1992 | 135 | 0.030 |
Why?
|
| Taxoids | 2 | 2006 | 665 | 0.030 |
Why?
|
| Perineum | 2 | 2006 | 212 | 0.030 |
Why?
|
| Neurodegenerative Diseases | 1 | 2001 | 1089 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 2133 | 0.020 |
Why?
|
| Porphyrins | 1 | 2014 | 352 | 0.020 |
Why?
|
| Cyclophosphamide | 4 | 2004 | 2234 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 321 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1776 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2002 | 1677 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2011 | 1525 | 0.020 |
Why?
|
| Patient Selection | 2 | 2001 | 4252 | 0.020 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1993 | 199 | 0.020 |
Why?
|
| Cisplatin | 4 | 2006 | 1656 | 0.020 |
Why?
|
| Hospitals | 1 | 2005 | 3885 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2020 | 2925 | 0.020 |
Why?
|
| Prostate | 1 | 2000 | 1760 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 26309 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 1997 | 769 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2015 | 1647 | 0.020 |
Why?
|
| Crosses, Genetic | 2 | 2003 | 751 | 0.020 |
Why?
|
| Microinjections | 1 | 1992 | 319 | 0.020 |
Why?
|
| DNA Repair | 3 | 2007 | 2050 | 0.020 |
Why?
|
| Cause of Death | 2 | 2003 | 3717 | 0.020 |
Why?
|
| Recurrence | 6 | 2006 | 8507 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2005 | 7841 | 0.020 |
Why?
|
| Interferon-gamma | 3 | 2008 | 3157 | 0.020 |
Why?
|
| Rats | 1 | 2008 | 23717 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1992 | 286 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1998 | 1480 | 0.020 |
Why?
|
| Learning | 2 | 2016 | 1754 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2003 | 1082 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 705 | 0.020 |
Why?
|
| Eating | 1 | 2018 | 1539 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1991 | 195 | 0.020 |
Why?
|
| Osteopontin | 2 | 2003 | 305 | 0.020 |
Why?
|
| Base Pairing | 1 | 2011 | 139 | 0.020 |
Why?
|
| Protein Transport | 1 | 2016 | 1944 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1998 | 1195 | 0.020 |
Why?
|
| Aftercare | 1 | 1997 | 915 | 0.020 |
Why?
|
| Cell Survival | 4 | 2004 | 5749 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 2355 | 0.020 |
Why?
|
| Intraoperative Period | 2 | 2005 | 512 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2002 | 1550 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 251 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 438 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2002 | 63 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 1999 | 1381 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2000 | 5990 | 0.020 |
Why?
|
| Skin | 2 | 2008 | 4499 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2004 | 1697 | 0.020 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 344 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2006 | 1606 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2000 | 1480 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 1993 | 966 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2004 | 370 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1992 | 640 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 1521 | 0.020 |
Why?
|
| Incidence | 4 | 2006 | 21527 | 0.020 |
Why?
|
| Glycosylation | 1 | 1992 | 1099 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 1999 | 1705 | 0.020 |
Why?
|
| Quality Control | 2 | 2003 | 834 | 0.020 |
Why?
|
| Radiography | 2 | 2014 | 6968 | 0.020 |
Why?
|
| Remission Induction | 5 | 1994 | 2413 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2001 | 2340 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2015 | 1675 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 1969 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2016 | 2741 | 0.020 |
Why?
|
| Actins | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1995 | 908 | 0.020 |
Why?
|
| Dacarbazine | 3 | 1998 | 552 | 0.020 |
Why?
|
| Lung | 1 | 2007 | 10068 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1062 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1991 | 403 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1992 | 1750 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2010 | 333 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2019 | 2926 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2006 | 4033 | 0.020 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2009 | 183 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2008 | 142 | 0.020 |
Why?
|
| Neutrophils | 1 | 2001 | 3782 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2006 | 8928 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 12985 | 0.020 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 325 | 0.020 |
Why?
|
| Oncolytic Virotherapy | 1 | 2014 | 520 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1902 | 0.020 |
Why?
|
| Hemoglobinopathies | 1 | 2008 | 101 | 0.020 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2008 | 116 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2334 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2005 | 13050 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 5444 | 0.020 |
Why?
|
| Guidelines as Topic | 2 | 2005 | 1394 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2005 | 2846 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 1055 | 0.020 |
Why?
|
| Adiposity | 1 | 2018 | 1892 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2001 | 6258 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2007 | 42 | 0.020 |
Why?
|
| Antibodies | 1 | 1995 | 2421 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1999 | 6507 | 0.020 |
Why?
|
| RNA, Messenger | 4 | 2008 | 12795 | 0.020 |
Why?
|
| 1-Carboxyglutamic Acid | 1 | 1987 | 19 | 0.020 |
Why?
|
| Diarrhea | 1 | 2014 | 1317 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 1997 | 1761 | 0.020 |
Why?
|
| Guanine | 1 | 2008 | 280 | 0.020 |
Why?
|
| Glutamates | 1 | 2008 | 384 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 1384 | 0.020 |
Why?
|
| DNA, Neoplasm | 3 | 2002 | 1741 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 238 | 0.020 |
Why?
|
| Factor IX | 1 | 1987 | 76 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1998 | 2779 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2007 | 95 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 326 | 0.020 |
Why?
|
| Coloring Agents | 2 | 2001 | 565 | 0.020 |
Why?
|
| Happiness | 1 | 1988 | 170 | 0.020 |
Why?
|
| Bystander Effect | 1 | 2006 | 89 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2006 | 176 | 0.020 |
Why?
|
| Anthropometry | 2 | 2002 | 1336 | 0.020 |
Why?
|
| Contrast Media | 2 | 2014 | 5329 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 2413 | 0.020 |
Why?
|
| Life Style | 1 | 2018 | 3926 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2006 | 220 | 0.020 |
Why?
|
| Retinoblastoma-Binding Protein 4 | 1 | 2005 | 12 | 0.020 |
Why?
|
| Virus Replication | 1 | 2014 | 2457 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 682 | 0.020 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 549 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2001 | 4858 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 748 | 0.020 |
Why?
|
| United States | 3 | 2016 | 72945 | 0.020 |
Why?
|
| Genes, DCC | 1 | 2005 | 10 | 0.020 |
Why?
|
| Polyvinyl Alcohol | 1 | 2006 | 74 | 0.020 |
Why?
|
| Attitude to Health | 2 | 2005 | 2021 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 1997 | 4525 | 0.020 |
Why?
|
| Drug Industry | 2 | 2003 | 791 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1892 | 0.020 |
Why?
|
| Multigene Family | 1 | 2008 | 1081 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2006 | 294 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2016 | 3138 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 8352 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2062 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3427 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2005 | 109 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2005 | 114 | 0.020 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2005 | 32 | 0.020 |
Why?
|
| Procarbazine | 2 | 1997 | 172 | 0.020 |
Why?
|
| Mechlorethamine | 2 | 1997 | 129 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 2971 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2004 | 4019 | 0.010 |
Why?
|
| Kinetics | 1 | 1992 | 6288 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 200 | 0.010 |
Why?
|
| Pregnancy | 3 | 2016 | 30236 | 0.010 |
Why?
|
| History, 18th Century | 1 | 2005 | 206 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3250 | 0.010 |
Why?
|
| Nucleotides | 1 | 2007 | 454 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 610 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1992 | 1540 | 0.010 |
Why?
|
| Depression | 1 | 2004 | 8225 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2004 | 2456 | 0.010 |
Why?
|
| Decision Trees | 1 | 2006 | 508 | 0.010 |
Why?
|
| Cell Movement | 1 | 2016 | 5204 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 305 | 0.010 |
Why?
|
| Karyotyping | 1 | 2006 | 1176 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 2671 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2006 | 412 | 0.010 |
Why?
|
| Farnesyltranstransferase | 1 | 2004 | 70 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 2005 | 193 | 0.010 |
Why?
|
| Protein Prenylation | 1 | 2004 | 69 | 0.010 |
Why?
|
| Flow Cytometry | 3 | 2002 | 5890 | 0.010 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 545 | 0.010 |
Why?
|
| Nutritional Status | 2 | 2003 | 1621 | 0.010 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 273 | 0.010 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2004 | 85 | 0.010 |
Why?
|
| Paris | 1 | 2003 | 40 | 0.010 |
Why?
|
| Bleomycin | 2 | 1997 | 492 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 150 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 7119 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2005 | 342 | 0.010 |
Why?
|
| Control Groups | 1 | 2003 | 107 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1988 | 642 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 2004 | 195 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1991 | 2730 | 0.010 |
Why?
|
| Urethane | 1 | 2002 | 37 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 267 | 0.010 |
Why?
|
| Genetic Testing | 2 | 2007 | 3591 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 3738 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2011 | 1958 | 0.010 |
Why?
|
| Blotting, Western | 2 | 2002 | 5022 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1991 | 2115 | 0.010 |
Why?
|
| Body Image | 1 | 1988 | 645 | 0.010 |
Why?
|
| Microspheres | 1 | 2006 | 774 | 0.010 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 110 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1987 | 1134 | 0.010 |
Why?
|
| Phenylhydrazines | 1 | 2002 | 28 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1992 | 5388 | 0.010 |
Why?
|
| Leukopoiesis | 1 | 2002 | 54 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2006 | 589 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 861 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 474 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2002 | 116 | 0.010 |
Why?
|
| Rosaniline Dyes | 1 | 2002 | 50 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 478 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 505 | 0.010 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 808 | 0.010 |
Why?
|
| Biological Assay | 1 | 2005 | 626 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 317 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2004 | 663 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2005 | 634 | 0.010 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2002 | 117 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 2198 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 2002 | 268 | 0.010 |
Why?
|
| Hematoxylin | 1 | 2001 | 61 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2002 | 164 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2001 | 70 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 573 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 14762 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 816 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 2931 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2004 | 505 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 3724 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12808 | 0.010 |
Why?
|
| Reminder Systems | 1 | 2004 | 389 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 450 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2016 | 9358 | 0.010 |
Why?
|
| New York City | 1 | 2003 | 736 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5873 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1852 | 0.010 |
Why?
|
| Zinc | 1 | 2005 | 675 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 622 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 878 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 1157 | 0.010 |
Why?
|
| Decision Making | 2 | 2005 | 3951 | 0.010 |
Why?
|
| Dipyridamole | 1 | 1980 | 143 | 0.010 |
Why?
|
| Lymphography | 1 | 2001 | 189 | 0.010 |
Why?
|
| Amenorrhea | 1 | 2004 | 470 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 8065 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1988 | 1432 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 1135 | 0.010 |
Why?
|
| Thyroxine | 1 | 2004 | 665 | 0.010 |
Why?
|
| Histones | 1 | 2010 | 2595 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2004 | 488 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2003 | 636 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 1595 | 0.010 |
Why?
|
| Prednisone | 2 | 1997 | 1566 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 184 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 462 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 792 | 0.010 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 1999 | 24 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2005 | 24299 | 0.010 |
Why?
|
| Sleep Stages | 1 | 2004 | 705 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2003 | 562 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 198 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2003 | 557 | 0.010 |
Why?
|
| Mammography | 2 | 2004 | 2429 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 928 | 0.010 |
Why?
|
| Cystectomy | 1 | 2004 | 603 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6514 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 1117 | 0.010 |
Why?
|
| Metalloproteins | 1 | 1999 | 98 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2005 | 1139 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 1244 | 0.010 |
Why?
|
| TCF Transcription Factors | 1 | 1999 | 138 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1987 | 1965 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2002 | 1159 | 0.010 |
Why?
|
| Immunotherapy | 2 | 2006 | 4747 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2010 | 1882 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2013 | 4427 | 0.010 |
Why?
|
| Vulnerable Populations | 1 | 2004 | 718 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 1014 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 2209 | 0.010 |
Why?
|
| ras Proteins | 1 | 2004 | 1055 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 1999 | 228 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 784 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 1968 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 2201 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 420 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1999 | 1057 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1998 | 304 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1993 | 8533 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 730 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 2746 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 706 | 0.010 |
Why?
|
| Obesity | 1 | 2000 | 13090 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 3624 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 1742 | 0.010 |
Why?
|
| Heart | 1 | 2011 | 4425 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1998 | 318 | 0.010 |
Why?
|
| Vertebrates | 1 | 1999 | 227 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 1999 | 453 | 0.010 |
Why?
|
| Teniposide | 1 | 1997 | 11 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7869 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2001 | 768 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2005 | 1193 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1999 | 281 | 0.010 |
Why?
|
| Biophysics | 1 | 1998 | 376 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 1996 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 1838 | 0.010 |
Why?
|
| Kidney | 1 | 1992 | 7073 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2004 | 1274 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 3431 | 0.010 |
Why?
|
| Methotrexate | 1 | 2004 | 1719 | 0.010 |
Why?
|
| Colloids | 1 | 1997 | 125 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 881 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 2726 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1988 | 2662 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2425 | 0.010 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2000 | 306 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 3618 | 0.010 |
Why?
|
| Clone Cells | 1 | 2000 | 1670 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1555 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 1997 | 122 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 830 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 1409 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 1614 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 1492 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1980 | 519 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 1377 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1997 | 131 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2006 | 2747 | 0.010 |
Why?
|
| Skin Pigmentation | 1 | 1997 | 278 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2000 | 1334 | 0.010 |
Why?
|
| Epirubicin | 1 | 1994 | 82 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2002 | 1422 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1999 | 2177 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2003 | 3605 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1998 | 414 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15912 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 987 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 698 | 0.010 |
Why?
|
| Sarcoma, Synovial | 1 | 1995 | 157 | 0.010 |
Why?
|
| Growth Substances | 1 | 1996 | 759 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 2715 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2429 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 313 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2002 | 2328 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 1133 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 2228 | 0.010 |
Why?
|
| Testosterone | 1 | 2004 | 2495 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 678 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 2171 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 614 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 1999 | 1144 | 0.010 |
Why?
|
| Androgens | 1 | 2000 | 1280 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2006 | 2787 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2001 | 4143 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1992 | 259 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1997 | 702 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 3401 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2002 | 18329 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1993 | 412 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1980 | 1473 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 1980 | 1464 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1991 | 20 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10451 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2186 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5502 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 774 | 0.010 |
Why?
|
| Drosophila | 1 | 1999 | 1509 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 3429 | 0.010 |
Why?
|
| Aortic Valve | 1 | 1980 | 1966 | 0.010 |
Why?
|
| Health Education | 1 | 1997 | 1060 | 0.010 |
Why?
|
| Colon | 1 | 1998 | 1797 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 1993 | 564 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2005 | 4526 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1998 | 2474 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 3070 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 3837 | 0.000 |
Why?
|
| Neutropenia | 1 | 1994 | 895 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1992 | 1529 | 0.000 |
Why?
|
| Psychometrics | 1 | 1998 | 3060 | 0.000 |
Why?
|
| Mental Health | 1 | 2003 | 3269 | 0.000 |
Why?
|
| Comorbidity | 1 | 2003 | 10580 | 0.000 |
Why?
|
| Lysine | 1 | 1992 | 998 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2678 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2005 | 22248 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 2470 | 0.000 |
Why?
|
| Palliative Care | 1 | 2002 | 3640 | 0.000 |
Why?
|
| Mitosis | 1 | 1992 | 1176 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 4853 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1991 | 2127 | 0.000 |
Why?
|
| Education, Medical | 1 | 1997 | 1744 | 0.000 |
Why?
|
| Abdomen | 1 | 1991 | 1137 | 0.000 |
Why?
|
| Vitamin K | 1 | 1987 | 314 | 0.000 |
Why?
|
| Proteins | 1 | 1999 | 6002 | 0.000 |
Why?
|
| Public Health | 1 | 1997 | 2680 | 0.000 |
Why?
|
| Peptides | 1 | 1987 | 4347 | 0.000 |
Why?
|
| Thromboembolism | 1 | 1980 | 1003 | 0.000 |
Why?
|
| Delivery, Obstetric | 1 | 1980 | 949 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 20710 | 0.000 |
Why?
|